年内涨幅已超62%，港股创新药ETF（159567）继续走强，机构看好创新药产业发展趋势

Group 1 - The core viewpoint of the articles highlights the strong performance and positive outlook for the innovative drug sector in the Hong Kong stock market, with significant trading activity and growth in related ETFs [1][2] - The Hong Kong innovative drug ETF (159567) has seen a year-to-date increase of over 62% as of June 10, indicating robust investor interest and market momentum [1] - Major stocks within the innovative drug sector, such as Green Leaf Pharmaceutical, have experienced notable gains, contributing to the overall positive sentiment in the market [1] Group 2 - Multiple institutions express optimism regarding the future of the innovative drug industry, emphasizing its alignment with global trends and the ongoing value reconstruction of Chinese innovative drugs [2] - Financial institutions like Galaxy Securities and Shenwan Hongyuan highlight the potential for sustained recovery in the pharmaceutical market, with structural opportunities remaining available [2] - The innovative drug sector has shown consistent revenue growth and increased external licensing deals over the past three years, with expectations for significant product launches and business development activities in the near future [2]